HKSE - Delayed Quote HKD

VIVA BIOTECH (1873.HK)

1.480

-0.030

(-1.99%)

At close: April 25 at 4:08:21 PM GMT+8

Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection

Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP (Current Good Manufacturing Practices) on-site inspection by the U.S. Food and Drug Administration ("FDA"), and received the EIR (Establishment Inspection Report) from the FDA. This is the fourth time that Langhua Pharmaceutical has undergone and passed the on-site inspection by the FDA, indicating the effective operation of the Company's qua

PR Newswire 29 days ago

VBIZF
Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D

On March 27, 2025, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue during the Reporting Period achieved RMB1,986.7 million, gross profit amounted to RMB687.4 million and net profit recorded RMB222.0 million, a significant turnaround from a net loss of RMB99.8 million in the corresponding period of last year, mainly benefiting from the elimination of relevant financial adjustments due to the full repayment of convert

PR Newswire 30 days ago

VBIZF
Asian Penny Stocks Spotlight: Viva Biotech Holdings And Two More To Consider

Amidst global economic uncertainties, Asian markets have shown resilience, with a focus on growth strategies to navigate challenges such as trade tensions and inflationary pressures. In this context, penny stocks—often representing smaller or newer companies—continue to capture investor interest due to their potential for significant returns. While the term may seem outdated, these stocks can offer a blend of affordability and growth potential when backed by strong financials.

Simply Wall St. last month

E3B.SI

VBIZF
Discovering Opportunities: 3 Penny Stocks With Market Caps Over US$200M

As global markets navigate a mix of steady interest rates, fluctuating corporate earnings, and geopolitical uncertainties, investors are seeking opportunities in less conventional areas. Penny stocks, often seen as relics from past market eras, continue to offer intriguing possibilities for those willing to explore beyond the mainstream. These typically smaller or newer companies provide a blend of affordability and potential growth when backed by robust financial health.

Simply Wall St. 2 months ago

VBIZF
Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion

Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in drug research, development and manufacturing services, this milestone marks a significant step forward in the company's global expansion strategy. Viva Biotech aims to further enhance and deepen international collaboration networks, providing comprehensive one-stop CRO-CMC/CDMO services—from drug discovery and preclinical development to commercial ma

PR Newswire 4 months ago

VBIZF
Discover December 2024's Top Penny Stocks

Global markets have recently experienced a series of gains, with major indices such as the Dow Jones Industrial Average and S&P 500 Index reaching record intraday highs, despite geopolitical tensions and domestic policy shifts influencing investor sentiment. Amid these developments, the concept of penny stocks—often associated with smaller or newer companies—continues to capture interest due to their affordability and potential for growth. While the term may seem outdated, these stocks can...

Simply Wall St. 4 months ago

VBIZF

0909.HK
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms

On August 29, 2024, Viva Biotech Holdings Group ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that the Group achieved a revenue RMB981.8 million; and the Group's gross profit of RMB339.1 million. The Group's net profit amounted to RMB144.2 million, a significant improvement from the net profit of RMB13.7 million for the corresponding period of last year, mainly benefiting from the elimination of relevant financial adjustments due to the full repayment of convertib

PR Newswire 7 months ago

VBIZF

Performance Overview

Return	1873.HK	HANG SENG INDEX (^HSI)
YTD	+70.11%	+9.58%
1-Year	+164.29%	+27.17%
3-Year	-38.84%	+10.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

VIVA BIOTECH (1873.HK)

Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection

Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D

Asian Penny Stocks Spotlight: Viva Biotech Holdings And Two More To Consider

Discovering Opportunities: 3 Penny Stocks With Market Caps Over US$200M

Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion

Discover December 2024's Top Penny Stocks

Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms

Performance Overview